Lucid Diagnostics Inc. (NASDAQ:LUCD) Stock Has Average Target Price of $4.19 According to Brokerages

Posted by Brenda Bartman on Oct 15th, 2026

Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the five research firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $4.19.

LUCD has been the subject of a number of analyst reports. Needham & Company LLC restated a “buy” rating on shares of Lucid Diagnostics in a report on Thursday, October 1st. BTIG Research reiterated a “buy” rating and issued a $2.50 target price on shares of Lucid Diagnostics in a report on Monday, August 17th. Wall Street Zen downgraded Lucid Diagnostics from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Finally, Weiss Ratings lowered Lucid Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 18th.

View Our Latest Stock Analysis on LUCD

Institutional Investors Weigh In On Lucid Diagnostics

Several large investors have recently made changes to their positions in LUCD. Alyeska Investment Group L.P. bought a new stake in Lucid Diagnostics in the 2nd quarter valued at approximately $9,477,000. BlackRock Inc. bought a new stake in shares of Lucid Diagnostics in the second quarter worth $8,959,000. Two Seas Capital LP acquired a new position in Lucid Diagnostics during the second quarter worth $6,420,000. Sunbelt Securities Inc. boosted its holdings in Lucid Diagnostics by 134.4% during the first quarter. Sunbelt Securities Inc. now owns 900,013 shares of the company’s stock worth $1,035,000 after purchasing an additional 516,014 shares during the last quarter. Finally, XML Financial LLC lifted its position in Lucid Diagnostics by 44.8% during the 2nd quarter. XML Financial LLC now owns 323,195 shares of the company’s stock worth $346,000 after buying an additional 100,000 shares in the last quarter. Institutional investors own 74.01% of the company’s stock.

Lucid Diagnostics Stock Down 10.4%

LUCD opened at $0.54 on Friday. The company has a fifty day moving average price of $0.85 and a two-hundred day moving average price of $0.98. Lucid Diagnostics has a 52 week low of $0.50 and a 52 week high of $1.63.

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). The company had revenue of $1.47 million during the quarter, compared to analyst estimates of $1.43 million. As a group, research analysts predict that Lucid Diagnostics will post -0.23 earnings per share for the current fiscal year.

About Lucid Diagnostics

(Get Free Report)

Lucid Diagnostics Inc is a commercial-stage medical diagnostics company focused on detecting esophageal precancer and cancer at an earlier, more treatable stage. The company is a subsidiary of PAVmed Inc and develops diagnostic products intended to help identify patients at risk for esophageal adenocarcinoma, a cancer associated with Barrett’s esophagus and chronic gastroesophageal reflux disease.

Lucid’s primary products are EsoGuard, a laboratory-developed DNA test, and EsoCheck, a noninvasive, swallowable balloon device used to collect cells from the esophagus.